2. Cell Cycle/DNA Damage Apoptosis Epigenetics
  3. Sirtuin Apoptosis
  4. 1781223-80-0

1781223-80-0

Telisotuzumab Chemical Structure

1781223-80-0

Chemical Structure

  • Telisotuzumab
  • Synonym(s): ABT-700
  • CAS No: 1781223-80-0
    Molecular Weight: (146.1 kDa)
  • SMILES: [Telisotuzumab]

Biological Activity: Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers[1].

Cat. No. Product Name Purity Description
HY-P99391 Telisotuzumab 99.54% Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers.
HY-P99391A Telisotuzumab (powder) Telisotuzumab (ABT-700) (powder) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab (powder) binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab (powder) induces apoptosis. Telisotuzumab (powder) can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers.

References

[1]. Jieyi Wang, et al. Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification. BMC Cancer. 2016 Feb 16;16:105. [Content Brief]

Keywords:

TelisotuzumabTelisotuzumab (powder)